Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Cancer Genetics and Cytogenetics|September 15, 2005
Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9)Constantina Sambani, Roberta La Starza, Valentina Pierini, et al.
Annals of Hematology|June 6, 2024
Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapyAnthi Bouchla, Christina D Sotiropoulou, Christopher Esteb, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 6, 2012
Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraMaria Pagoni, Maria Garofalaki, Fotios Panitsas, et al.
Frontiers in Immunology|June 13, 2022
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological MalignanciesCristina Bergamaschi, Maria Pagoni, Margherita Rosati, et al.
International Journal of Hematology|November 6, 2016
A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in GreeceVasiliki Pappa, Achilles Anagnostopoulos, Eleni Bouronikou, et al.
Cancers|September 10, 2021
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective StudyEvangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, et al.
European Journal of Internal Medicine|May 31, 2021
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donorsEvangelos Terpos, Dimitris Stellas, Margherita Rosati, et al.
International Journal of Antimicrobial Agents|August 11, 2014
Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpointsMaria N Gamaletsou, George L Daikos, Thomas J Walsh, et al.
Leukemia Research|October 2, 2009
Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study GroupNikolaos J Tsagarakis, Nektaria A Kentrou, Konstantinos A Papadimitriou, et al.
Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Pageof 4